<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03307720</url>
  </required_header>
  <id_info>
    <org_study_id>AGONIST TRIGGER</org_study_id>
    <nct_id>NCT03307720</nct_id>
  </id_info>
  <brief_title>Agonist Versus Classical HCG Trigger (Poor Responders, Normoresponders and High Responders)</brief_title>
  <official_title>Agonist Trigger Versus Classical HCG Trigger in Controlled Ovarian Stimulation Among Three Different Subsets of Patients (Poor Responders, Normoresponders and High Responders)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ginegorama S.L.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ginegorama S.L.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Agonist triggering in controlled ovarian stimulation protocols is being used during last
      years (among high responder patients to avoid OHSS).

      Indeed, agonist triggering is more physiologic than HCG triggering. Investigators propose to
      compare the effectiveness of both types of trigger among three different subsets of patients:

        1. Poor responders.

        2. Normo-responders

        3. High responders Comparing both the number and the quality of achieved oocytes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During the last years, ovulation triggering in controlled ovarian stimulation protocols has
      been used specially to avoid hyperstimulation syndromes (OHSS). Indeed, the substitution of
      the classical HCG triggering by the agonist one, reduces almost to zero the risk of OHSS.

      On the other hand poor responder patients to ovarian stimulation represent a challenge in
      assisted reproduction. Defining poor responders is not easy, but we can define them as those
      patients with less than 4 eggs obtained after oocyte retrieval.

      Different strategies have been proposed to overcome this problem. In other words, to obtain
      more oocytes. These include an increase in FSH doses, an increase in FSH action by adding
      sensitizers agents.

      Among the possible strategies, investigators propose the agonist triggering. HCG (classical)
      triggering represents the use of a LH-like product (with a prolonged action). The
      administration of a GnRH agonist provoke the production and liberation of both FSH and LH.
      Thus, the pro-ovulatory action is more physiologic , and possibly, more effective.

      So, the use of a triggering protocol that nowadays is being used among high responders (thus
      reducing the OHSS risk) is proposed for both poor responder and normo-responder patients
      trying to achieve more oocytes, and specifically more mature oocytes.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 18, 2017</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>IVF patients enrolled either to HCG or agonist trigger ovulation induction</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mature oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of mature oocytes achieved after oocyte retrieval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relation mature oocytes/punctured oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Relation between the number of mature oocytes and the follicles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilized oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of fertilized oocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relation fertilized oocytes/achieved Mature oocytes</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Relation between the number of fertilized oocytes and the mature oocytes achieved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of blastocysts developed</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Number of blastocysts developed in each arm of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancelled cycles</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <description>Percentage of cancelled cycles</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Ovulation Induction</condition>
  <condition>In Vitro Fertilization (IVF)</condition>
  <condition>Infertility, Female</condition>
  <condition>Oocytes</condition>
  <arm_group>
    <arm_group_label>Poor responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Poor responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
Women scheduled for IVF treatment with 4 or less antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normo responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normo responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
Women scheduled for IVF treatment with more than 4 and less than 16 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High responders. Classical trigger</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: HCG trigger (Administration of recombinant HCG 250 UI subcutaneously 36 prior to oocyte retrieval.
Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High responders. Agonist trigger</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Agonist trigger (administration of 0,2 mg of Triptoreline subcutaneously 36 hours prior to oocyte retrieval)
Women scheduled for IVF treatment with more than 15 antral follicles in ultrasound assessment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin Releasing Hormone Agonists (GNRH-A)</intervention_name>
    <description>Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.</description>
    <arm_group_label>Poor responders. Agonist trigger</arm_group_label>
    <arm_group_label>Normo responders. Agonist trigger</arm_group_label>
    <arm_group_label>High responders. Agonist trigger</arm_group_label>
    <other_name>Agonist trigger</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human chorionic gonadotropin</intervention_name>
    <description>Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.</description>
    <arm_group_label>Poor responders. Classical trigger</arm_group_label>
    <arm_group_label>Normo responders. Classical trigger</arm_group_label>
    <arm_group_label>High responders. Classical trigger</arm_group_label>
    <other_name>HCG trigger</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women scheduled for IVF treatment.

          -  First ovarian stimulation

          -  Two ovaries present

          -  No previous ovarian surgery

          -  No contraindication for any of the assigned treatments

        Exclusion Criteria:

          -  Previous ovarian surgery.

          -  Previous IVF treatments.

          -  Absence of one ovary

          -  Presence of an endometrioma
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gorka Barrenetxea, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jon Iker Arambarri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Reproducción Bilbao. Universidad del País Vasco/Euskal Herriko Unibertsitatea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gorka Barrenetxea, PhD</last_name>
    <phone>00 34 605711484</phone>
    <email>gbarrenetxea@reproduccionbilbao.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amaia Garcia, PhD</last_name>
    <email>agarcia@reproduccionbilbao.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Reproduccion Bilbao Assisted Reproduction Center</name>
      <address>
        <city>Bilbao</city>
        <state>Bizkaia</state>
        <zip>48014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2017</study_first_submitted>
  <study_first_submitted_qc>October 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>December 8, 2017</last_update_submitted>
  <last_update_submitted_qc>December 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ginegorama S.L.</investigator_affiliation>
    <investigator_full_name>Gorka Barrenetxea</investigator_full_name>
    <investigator_title>Professor of Gynecology &amp; Obstetrics Universidad del País Vasco/Euskal Herriko Unibertsitatea. Medical Director of Reproducción Bilbao</investigator_title>
  </responsible_party>
  <keyword>agonist trigger</keyword>
  <keyword>Ovulation induction</keyword>
  <keyword>Controlled ovarian stimulation (COS)</keyword>
  <keyword>Poor responder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Chorionic Gonadotropin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

